Conclusions
- TA indications are common, with one patient in every five tested being a candidate for TA therapy; however, TA frequency varies tremendously across cancer types.
- Response durations (as measured by TOT) may not be tissue agnostic.
- Some TA approvals (e.g., TMB-H) extend beyond the initial study populations. RWE may extend TA indications to other drugs in the same class.